Related Experiment Video
Updated: Jun 22, 2026

In Vitro Analysis of E3 Ubiquitin Ligase Function
Published on: May 14, 2021
Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease
Monte S Willis1, Jonathan C Schisler, Cam Patterson
1Department of Pathology & Laboratory Medicine, Carolina Cardiovascular Biology Center, 2340B Medical Biomolecular Research Building, University of North Carolina, Chapel Hill, NC 27599-7525, USA.
Insights
The ubiquitin-proteasome system (UPS) maintains heart health by degrading proteins. Targeting specific UPS components, like E3 ubiquitin ligases, may offer safer cardiac disease therapies than broad proteasome inhibition.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Cellular Protein Degradation
Background:
- The heart requires constant protein quality control, managed by the ubiquitin-proteasome system (UPS).
- The UPS plays a specific role in cardiac hypertrophy, ischemic heart disease, and cardiomyopathies.
- Proteasome inhibitors show therapeutic potential in animal models but can be cardiotoxic in humans.
Purpose of the Study:
- To review the function of the UPS in cardiac disease.
- To explore the therapeutic potential of targeting specific UPS components for cardiac conditions.
Main Methods:
- Literature review of studies on the ubiquitin-proteasome system in cardiac disease.
- Analysis of research on proteasome inhibitors and E3 ubiquitin ligases in cardiovascular contexts.
Main Results:
- The UPS is crucial for maintaining cardiac protein homeostasis.
- Specific UPS components are implicated in various cardiac pathologies.
- Targeting E3 ubiquitin ligases presents a promising therapeutic avenue for cardiac diseases.
Conclusions:
- The UPS is a key regulator in cardiac health and disease.
- Targeting specific E3 ubiquitin ligases offers a potential strategy for novel cardiac therapies.
- Further research into UPS regulation is needed for effective cardiovascular treatments.
Abstract:
Over the course of 3 billion heartbeats in an average human lifetime, the heart must maintain constant protein quality control, including the coordinated and regulated degradation of proteins via the ubiquitin-proteasome system (UPS). Recent data highlight the specificity by which the UPS functions in the context of cardiac hypertrophy, ischemic heart disease and cardiomyopathies. Although curbing the appetite of the proteasome through the use of inhibitors in animal models of cardiac disease has proven effective experimentally, recent studies report proteasome inhibition as being cardiotoxic in some patients. Therefore, focusing on specific regulatory components of the proteasome, such as members of the E3 ubiquitin-ligase family of proteins, may hold promise for targeted therapeutics of cardiac disease. This review focuses on the UPS, its specific role in cardiac disease and opportunities for novel therapies.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Unfolded Protein Response
